(From the November 2013 Issue of MedStat)
$25.4 Million Awarded to Continue Critical “Bench to Bedside” Translational Research
The National Institutes of Health (NIH) has awarded a $25.4 million grant to The Ohio State University Center for Clinical and Translational Science (CCTS), a collaboration between The Ohio State University and Nationwide Children’s created to accelerate basic science discoveries into life-saving medical advances. Read the news release.
Study Shows Buying Breast Milk Online is Likely to Cause Illness in Infants
Results from a study led by Sarah A. Keim, PhD, principal investigator in the Center for Biobehavioral Health at The Research Institute found more than three-fourths of breast milk samples purchased over the Internet contained bacteria that can cause illness, and frequently exhibited signs of poor collection, storage or shipping practices. The study, published in the November issue of Pediatrics, is the first to examine the safety of selling breast milk to others over the Internet, a trend that has become more frequent in the past several years. Read the news release.
Fast Track Status for Spinal Muscular Atrophy Treatment
AveXis and BioLife, synthetic biology platform companies, announced that The Research Institute at Nationwide Children’s received Fast Track designation from the U.S. Food and Drug Administration for its scAAV9.CB.SMN gene therapy product for the treatment of spinal muscular atrophy. This new gene therapy product created by scientists at The Research Institute was granted Fast Track status after demonstrating preliminary effectiveness in mouse models of SMA, potentially addressing this unmet medical need. Read the news release.
Cardinal Health Donates $1 Million to Tissue Engineering Program
Cardinal Health recently donated $1 million to Nationwide Children’s to help advance the work and research of its Tissue Engineering Program. Tissue engineering is the process by which the child’s own cells are used to ‘grow’ new tissue or organs for repair of congenital defects, or defects that are present at birth. Christopher Breuer, MD, and Toshiharu Shinoka, MD, PhD, co-directors of the Tissue Engineering Program at Nationwide Children’s who came to the hospital from Yale University last year, were the first in the world to tissue engineer blood vessels and implant them in human infants for repair of congenital heart defects. Read the news release.